NCT06381154 - Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 6, 2024

Primary Completion Date

December 6, 2029

Study Completion Date

December 6, 2029

Conditions

Locally Advanced Pancreatic AdenocarcinomaMetastatic Pancreatic AdenocarcinomaStage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Pancreatic Adenocarcinoma

Interventions

PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT or PET/CT

PROCEDURE

Endoscopic Ultrasound

Undergo EUS

DRUG

Fluorouracil

Given IV

DRUG

Irinotecan

Given IV

DRUG

Leucovorin

Given IV

PROCEDURE

Lymph Node Biopsy

Undergo lymph node biopsy

PROCEDURE

Magnetic Resonance Imaging

Undergo PET/MRI

DRUG

Oxaliplatin

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

DRUG

Photodynamic Therapy

Undergo intratumoral photoradiation

PROCEDURE

Positron Emission Tomography

Undergo PET/CT and PET/MRI

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Verteporfin

Given IV

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester